Kayyem Jon Faiz's Form 4 filing
Inhibrx Biosciences, Inc. (INBX) · filed Nov 22, 2024
- Accession no.
- 0002007919-24-000064
- Filed
- Nov 22, 2024
- Trade date
- Nov 19-20, 2024
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $1.52M. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kayyem Jon FaizCIK 0001366268 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 19, 2024 | Common Stock | PPurchaseAcquired | +34,843 | $14.23 | +$495,815.89 | 51,093 | Indirect | |
| Nov 19, 2024 | Common Stock | PPurchaseAcquired | +34,843 | $14.23 | +$495,815.89 | 51,093 | Indirect | |
| Nov 20, 2024 | Common Stock | PPurchaseAcquired | +18,750 | $14.19 | +$266,062.5 | 69,843 | Indirect | |
| Nov 20, 2024 | Common Stock | PPurchaseAcquired | +18,750 | $14.19 | +$266,062.5 | 69,843 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.